A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer

EARLY_PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2012

Primary Completion Date

June 30, 2014

Study Completion Date

July 31, 2014

Conditions
Resectable Pancreatic Cancer
Interventions
DRUG

LDE-225

LDE-225 capsules will be administered as a fixed dose of 800 mg daily for two weeks.

Trial Locations (1)

08901

Rutgers Cancer Institute of New Jersey, New Brunswick

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Rutgers Cancer Institute of New Jersey

OTHER

collaborator

National Cancer Institute (NCI)

NIH

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Rutgers, The State University of New Jersey

OTHER